COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants - surveillance results from southern Sweden, December 2021 to March 2022.
Euro Surveill
; 27(18)2022 05.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1834267
ABSTRACT
We compared vaccine effectiveness against severe COVID-19 between December 2021 and March 2022 when Omicron BA.1 and BA.2 were the dominating SARS-CoV-2 variants in Scania county, Sweden. Effectiveness remained above 80% after the transition from BA.1 to BA.2 among people with at least three vaccine doses but the point estimate decreased markedly to 54% among those with only two doses. Protection from prior infection was also lower after the transition to BA.2. Booster vaccination seems necessary to maintain sufficient protection.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
SARS-CoV-2
/
COVID-19
Tipo de estudio:
Estudio experimental
/
Estudio observacional
Tópicos:
Vacunas
/
Variantes
Límite:
Humanos
País/Región como asunto:
Europa
Idioma:
Inglés
Asunto de la revista:
Enfermedades Transmisibles
Año:
2022
Tipo del documento:
Artículo
País de afiliación:
1560-7917.ES.2022.27.18.2200322
Similares
MEDLINE
...
LILACS
LIS